Fasting Triglycerides: Longevity-Medicine Target Ranges

The direct answer

Fasting triglycerides are the concentration of triglyceride-carrying lipoproteins (mainly VLDL) measured in blood after 9 to 12 hours without food. The U.S. ATP III classification, carried into the 2018 ACC/AHA cholesterol guideline, sets "normal" at below 150 mg/dL, with 150 to 199 mg/dL borderline high, 200 to 499 mg/dL high, and 500 mg/dL or above very high. A fasting triglyceride level of 150 mg/dL or higher is also one of five criteria used to diagnose metabolic syndrome. Separately, several longevity-medicine practitioners advocate a stricter target below 100 mg/dL, based on the observation in large population cohorts that cardiovascular risk begins climbing well before triglycerides reach the 150 mg/dL clinical threshold. That lower number reflects a clinical judgment about optimization, not an FDA, ATP III, or ACC/AHA-defined disease threshold, and it has not been tested as a treatment target in a randomized outcomes trial.

This distinction matters for how a reader should act on a result. A triglyceride level of 120 mg/dL is unambiguously "normal" by every guideline in use today; whether it is worth actively lowering through diet, exercise, or further testing is a judgment call, not a diagnosis.

What fasting triglycerides measure, and why fasting matters

Triglycerides are the body's main storage form of dietary and hepatically synthesized fat, circulating packaged inside very-low-density lipoprotein (VLDL) particles. A fasting draw removes the variable contribution of chylomicrons carrying fat absorbed from a recent meal, giving a more stable and reproducible number that better reflects hepatic VLDL output and the activity of lipoprotein lipase, the enzyme that clears triglyceride-rich particles from circulation.

A non-fasting sample can run meaningfully higher than a fasting one in the same person on the same day, which is one reason fasting sampling is preferred when triglycerides are used to calculate LDL-C by the Friedewald equation; that equation becomes unreliable at very high triglyceride levels regardless of fasting status.

Hepatic production of triglycerides (de novo lipogenesis) is driven mainly by excess dietary carbohydrate and fructose intake rather than dietary fat itself, in the modern metabolic phenotype most clinicians encounter. Alcohol is an independent driver: even modest regular intake can raise fasting triglycerides noticeably in people who are genetically predisposed to triglyceride elevation. Uncontrolled type 2 diabetes and hypothyroidism both impair lipoprotein lipase activity and are common secondary causes worth ruling out when a triglyceride result is unexpectedly high without an obvious dietary explanation; a reasonable workup includes a hemoglobin A1c and thyroid-stimulating hormone (TSH) test.

Guideline reference ranges

The ATP III classification from the National Cholesterol Education Program, carried into the 2018 ACC/AHA cholesterol guideline, remains the most widely used framework in U.S. clinical practice.

ATP III also designates a fasting triglyceride level of 150 mg/dL or higher as one of five criteria for metabolic syndrome, alongside elevated waist circumference, elevated fasting glucose, elevated blood pressure, and low HDL-C. Meeting three or more of the five criteria is associated with substantially higher risk of type 2 diabetes and cardiovascular disease compared with meeting none, though the exact magnitude varies across the studies that have examined this.

The harmonized definition later endorsed jointly by several cardiometabolic organizations, including the International Diabetes Federation and the American Heart Association, kept the 150 mg/dL triglyceride cut-point unchanged. It also popularized the triglyceride-to-HDL ratio (calculated in mg/dL units) as a rough surrogate for insulin resistance and a small, dense LDL particle pattern; a ratio above roughly 3.0 is generally treated as a flag worth investigating further, though it is not itself a diagnostic criterion in any guideline.

Where the <100 mg/dL longevity target comes from, and its limits

The 150 mg/dL "normal" threshold was set as a population disease-risk cutoff, not as a physiologic optimum. Several longevity-medicine clinicians instead point to cohort studies suggesting that cardiovascular risk rises in a graded fashion starting at levels well below 150 mg/dL, and have adopted 100 mg/dL as a practical, lower target.

Large prospective cohorts, including Danish population studies and analyses drawn from the Women's Health Study, have reported that people in the highest triglyceride categories carry meaningfully higher cardiovascular event rates than those in the lowest categories, and that this gradient is detectable at levels still considered "normal" by ATP III. The exact hazard ratios and quintile cutoffs vary across these publications, and the specific figures often quoted for these studies deserve verification against the original paper before being repeated as fixed numbers; readers should treat this as a real but imprecisely quantified association rather than a validated risk calculator.

At the level of biology, elevated fasting triglycerides are a proxy for a higher number of circulating VLDL particles and their remnants (sometimes called intermediate-density lipoprotein, or IDL). Mendelian randomization studies have linked triglyceride-rich lipoprotein remnant cholesterol to atherosclerosis independent of LDL-C, which is the mechanistic argument for treating triglycerides as more than a bystander marker. What has not been established is that deliberately driving a "normal" triglyceride level down toward 100 mg/dL, in someone with no other risk factors, changes hard cardiovascular outcomes. No randomized trial has tested triglyceride-lowering to a below-100 mg/dL target as its primary strategy in a low-risk population.

A decision framework for interpreting your fasting triglyceride result

This framework is intended to help a reader (and their clinician) decide what a given number should trigger, not to replace individualized medical advice.

Exceptions that change the picture: a single non-fasting sample, a recent binge of alcohol or refined carbohydrate, poorly controlled diabetes, untreated hypothyroidism, oral estrogen therapy, or use of certain antipsychotics (notably olanzapine and clozapine) can all push a result upward independent of baseline metabolic health. A high triglyceride level in any of these contexts should prompt looking for the confounder before assuming it reflects a stable metabolic state.

Fasting triglycerides and MASLD (formerly NAFLD)

The condition previously called non-alcoholic fatty liver disease was renamed metabolic-associated steatotic liver disease (MASLD) following a 2023 multisociety Delphi consensus. MASLD is diagnosed by hepatic steatosis on imaging or biopsy plus at least one of five cardiometabolic risk factors, one of which is a fasting triglyceride level of 150 mg/dL or higher, or being on triglyceride-lowering pharmacotherapy. This makes fasting triglycerides a formal diagnostic input for MASLD rather than an incidental association.

Mechanistically, the same hepatic process (de novo lipogenesis driven by excess dietary carbohydrate and fructose) that raises fasting triglycerides also tends to deposit fat in the liver, which is why an elevated or rising triglyceride level is sometimes used as an inexpensive interim marker of hepatic fat trend between imaging studies. Whether triglyceride levels independently predict fibrosis progression in biopsy-confirmed disease, and by how much, is an area with published research but real heterogeneity across studies; specific numeric claims about fibrosis progression rates by triglyceride threshold should be checked against the primary literature before being treated as settled.

Cardiovascular risk beyond LDL-C: what the trial evidence actually shows

Statin therapy and LDL-C lowering remain the primary evidence-based approach to cardiovascular prevention. Residual cardiovascular risk persists in many statin-treated patients even with low LDL-C, and elevated triglycerides (and the remnant cholesterol they carry) are one candidate contributor to that residual risk.

The REDUCE-IT trial, a large randomized trial of statin-treated patients with elevated triglycerides (roughly 135 to 499 mg/dL) and established cardiovascular disease or diabetes plus an additional risk factor, found that high-dose icosapent ethyl (a purified EPA formulation) reduced major cardiovascular events relative to placebo over several years of follow-up. The STRENGTH trial, testing a mixed EPA/DHA omega-3 formulation in a comparable population, found no significant cardiovascular benefit. The divergence between these two trials is not fully resolved; the leading explanation in the literature is that pure EPA may have anti-inflammatory or membrane effects that mixed EPA/DHA formulations do not share, but this remains a hypothesis rather than a settled mechanism. In current U.S. practice, only icosapent ethyl (brand name Vascepa) carries FDA approval specifically for cardiovascular risk reduction in statin-treated patients with elevated triglycerides; other omega-3 products, including over-the-counter fish oil, do not have that approval and should not be assumed to carry the same benefit.

The 2019 ESC/EAS dyslipidemia guideline introduced "remnant cholesterol" (total cholesterol minus LDL-C minus HDL-C) as a distinct measure worth considering in cardiovascular risk assessment, on the reasoning that triglyceride-rich remnant particles are directly atherogenic. Fasting triglycerides are a practical, low-cost stand-in for remnant cholesterol when advanced lipoprotein particle testing (NMR or ion mobility) is not available, but the two are not identical, and a clinician interpreting a borderline triglyceride result should keep that distinction in mind.

What raises fasting triglycerides

Diet. Sugar-sweetened beverages, refined carbohydrates, and excess fructose are the most modifiable dietary drivers of elevated fasting triglycerides. Alcohol, even at modest intake, adds meaningfully in people with genetic susceptibility (for example, APOC3 or LPL gene variants).

Genetics. Familial hypertriglyceridemia and familial combined hyperlipidemia together affect a meaningful minority of adults and can drive fasting triglycerides well above 400 mg/dL despite an otherwise healthy lifestyle. Severe elevation above roughly 500 to 1,000 mg/dL should prompt evaluation for lipoprotein lipase deficiency or APOC2 mutations, since acute pancreatitis risk rises sharply at these levels.

Hormones and medications. Oral estrogen increases hepatic VLDL secretion and can raise fasting triglycerides; transdermal estradiol, which bypasses first-pass liver metabolism, has a more neutral effect and is the preferred option for women with elevated baseline triglycerides who need menopausal hormone therapy. Tamoxifen, beta-blockers, thiazide diuretics, certain second-generation antipsychotics (notably olanzapine and clozapine), and glucocorticoids can all raise fasting triglycerides through distinct mechanisms and are worth reviewing as part of any unexplained elevation.

Metabolic disease. Uncontrolled type 2 diabetes and hypothyroidism both impair lipoprotein lipase clearance of triglyceride-rich particles and are common, treatable secondary causes.

Lowering fasting triglycerides: what the evidence supports

Diet. Reducing refined carbohydrate intake, eliminating sugar-sweetened beverages, and cutting alcohol are first-line and typically produce a measurable drop within weeks to a couple of months, though the exact magnitude varies by starting level and adherence. Meta-analyses of randomized trials comparing lower-carbohydrate to lower-fat diets generally favor lower-carbohydrate approaches for triglyceride reduction specifically.

Exercise. Regular moderate-intensity aerobic activity lowers fasting triglycerides through improved skeletal-muscle lipoprotein lipase activity, with larger absolute reductions in people who start with higher triglycerides.

Weight loss. Weight reduction lowers fasting triglycerides roughly in proportion to the amount lost. The STEP-1 trial of once-weekly subcutaneous semaglutide 2.4 mg reported substantial average weight loss over 68 weeks in adults with overweight or obesity, with accompanying improvements in several cardiometabolic markers including triglycerides; readers should note this trial was designed around weight loss as the primary endpoint, not triglyceride reduction specifically.

Medications.

• Fibrates (fenofibrate preferred over gemfibrozil in statin-combination therapy, due to a lower drug-interaction and myopathy profile) reduce triglycerides substantially by increasing lipoprotein lipase activity and reducing VLDL secretion.
• High-dose prescription omega-3 fatty acids lower triglycerides, with icosapent ethyl (Vascepa) additionally carrying FDA approval for cardiovascular risk reduction in the statin-treated, elevated-triglyceride population described above (current as of this writing; confirm against the current FDA label before relying on this for a specific patient).
• Niacin lowers triglycerides but two large outcome trials (AIM-HIGH and HPS2-THRIVE) found no incremental cardiovascular benefit when added to statin therapy, and niacin carries meaningful flushing and hepatotoxicity risk. It is now generally reserved for refractory cases.
• Statins lower triglycerides modestly as a secondary effect of reducing VLDL production; they are not prescribed as first-line triglyceride-lowering therapy.

Reading results as a trend, not a single number

Fasting triglycerides vary meaningfully from day to day in the same person, which is one reason the ACC/AHA guideline favors basing treatment decisions on the average of two fasting measurements taken at least a week apart, particularly when a result falls in the borderline-high range. Tracking the triglyceride-to-HDL ratio across visits can add useful context for insulin sensitivity trends without the cost of advanced particle testing, though it is a surrogate marker, not a diagnostic test in its own right.

A note on emerging mechanistic research

Some laboratory and rodent research has explored regulators of glucose metabolism and fat storage, including work on the protein klotho, as potential upstream contributors to insulin resistance and obesity. One such study examined dietary and genetic effects of inhibiting klotho function on glucose metabolism and obesity in animal models (PubMed). This line of research is mechanistic and largely preclinical; it has not established a clinical triglyceride target or a treatment recommendation, and it should not be read as supporting any specific triglyceride number in humans. It is included here only as an example of the kind of upstream biology researchers are exploring, not as evidence for a longevity-medicine threshold.

Special situations worth flagging with a clinician

Women considering or on menopausal hormone therapy. Oral estrogen tends to raise fasting triglycerides through increased hepatic VLDL secretion; transdermal estradiol is generally considered a more triglyceride-neutral option and is often preferred for women who start with an elevated baseline.

People with type 2 diabetes. Insulin resistance impairs lipoprotein lipase and promotes VLDL overproduction, so elevated triglycerides are common in this group. Fenofibrate has been studied for its effect on diabetic microvascular complications, including retinopathy, in large randomized trials, though the size and consistency of that specific benefit across trials is a point that deserves review with a treating clinician rather than a fixed number repeated here.

Very high triglycerides (roughly 500 mg/dL or above). This is not a "recheck in three months" situation. Acute pancreatitis risk rises sharply at very high levels, and same-week or urgent evaluation is appropriate, especially with any abdominal pain, nausea, or vomiting.

What is established, what is plausible, and what is not established

Established: ATP III/ACC-AHA reference ranges and the metabolic syndrome triglyceride threshold of 150 mg/dL; the 2023 Delphi MASLD criteria including a triglyceride component; FDA approval of icosapent ethyl for cardiovascular risk reduction in a defined statin-treated, elevated-triglyceride population; the general direction of effect for diet, exercise, weight loss, fibrates, and prescription omega-3s on fasting triglyceride levels; sharply rising pancreatitis risk at very high triglyceride levels.

Plausible but unproven: that a fasting triglyceride target below 100 mg/dL, pursued in someone with no other metabolic risk factors, improves hard health outcomes beyond what is achieved by staying under the 150 mg/dL clinical threshold; the precise numeric hazard ratios often quoted from population cohort studies, which vary across publications and deserve verification before being treated as fixed; the exact contribution of triglycerides, independent of other metabolic syndrome components, to fibrosis progression in MASLD.

Not established: any individualized target, dosing, or treatment decision for a specific patient, which requires a clinician who has reviewed the full clinical picture, not a general reference range.